Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Why Rheumatologists Should Ask Patients About Drug Use

Larry Beresford  |  Issue: September 2016  |  September 8, 2016

Some patients with substance use disorders may find it difficult to stop taking the drug that triggered their rheumatologic disorder, Dr. Graf acknowledged. And some patients using drugs like cocaine may not fit the stereotypical profile of a drug user. “Even with someone you wouldn’t expect to be using these drugs, it’s a mistake to assume that it’s not a concern. In fact, cocaine use is prevalent in all aspects of society.” An estimated 1.9 million Americans actively used the illegal drug in 2008.

‘It’s important for rheumatologists to have a generalized understanding of the drugs their patients may take, legal or not, that [have an] impact on autoimmune diseases.’ —Dr. Graf

Varieties of Drug Manifestations

There are many ways that cocaine can trigger inflammatory responses. These include blood vessel diseases, vasoconstriction and cocaine-associated midline destructive lesions that start with chronic sinusitis and mimic granulomatosis with polyangiitis, as well as a host of garden variety rheumatologic disorders and reports of more unusual types of cocaine-associated vasculitis. “Cocaine is associated with well-described autoimmune disorders,” Dr. Graf said. Treatment is based on recognizing the disease and encouraging cessation of cocaine use. There is also some case report-level evidence for using high-dose methylprednisolone.

Less well described are rheumatologic disorders directly linked with heroin, but these include membranoproliferative glomerulonephritis, other renal diseases and amyloidosis. Other vascular syndromes are associated with methamphetamines, MDMA (ecstasy), ADHD medications, such as Adderall and Ritalin, and other prescription medications. Even over-the-counter cold preparations, such as pseudoephedrine, can induce vasculopathy. Other examples include drug-induced lupus, hydralazine-induced vasculitis, pulmonary hypertension and necrotizing glomerulonephritis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“We see a lot of things that don’t exactly fit the typical disease. You have to ask yourself: Is something else going on?” Dr. Graf said. “We often don’t know, but these patients may be losing tolerance to multiple antibodies and antigens,” he adds. For the front-line rheumatologist, urine toxicology screening can detect cocaine metabolites for up to 72 hours, but won’t detect levamisole, for which LC Tandem mass spectrometry is needed. Another tool for the doctor is to screen for anti-neutrophil cytoplasmic antibodies with fluorescence imaging.


Larry Beresford is an Oakland, Calif.-based freelance medical journalist.

Reference

  1. SAMHSA. Nationwide public health alert issued concerning life-threatening risk posed by cocaine laced with veterinary anti-parasite drug. Press Release. 2009 Sep 21. http://www.samhsa.gov/newsroom/press-announcements/200909210445.
ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsPractice Support Tagged with:California Rheumatology Alliance 2016Diagnosisdrug usepatient careRheumatic Diseaserheumatologist

Related Articles

    Fellow’s Forum Case Report: True Vasculitis or Vasculitis Mimic?

    October 1, 2012

    Rheumatologists face the emerging picture of cocaine and levamisole-associated vasculopathy in clinical practice

    Turn Down the Pain Volume

    October 1, 2009

    Fibromyalgia’s evolution from discrete entity to prototypical central pain syndrome

    Rheumatologists Treating Patients with HIV Face Treatment, Diagnostic Challenges

    Rheumatologists Treating Patients with HIV Face Treatment, Diagnostic Challenges

    June 15, 2017

    Rheumatologists treating HIV patients in 2017 must think through many important factors as this population ages. As we continue to learn, rheumatologists must consider important drug–drug interactions, relatively uncommon rheumatological presentations of HIV, as well as specific diagnostic challenges. Working closely with infectious disease specialists is the best way to achieve optimum care for this…

    ilusmedical / shutterstock.com

    The State of Clinical Research in Vasculitis: 2021

    January 19, 2021

    It is an exciting time in the world of vasculitis research. More clinical studies and trials are being conducted now than at any time in history. In the past ten years, four drugs have been approved by the U.S. Food & Drug Administration (FDA) and other regulatory agencies specifically for the treatment of vasculitis: Rituximab…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences